LDS/Medical Tests/Narcolepsy (HLA-DQB1*06:02P) Genotyping

Narcolepsy (HLA-DQB1*06:02P) Genotyping

Narcolepsy is a chronic sleep disorder characterized by: excessive daytime sleepiness, disrupted nocturnal sleep, rapid eye movement sleep (REM sleep) occurring at onset of sleep, and cataplexy. Other variable symptoms also associated with narcolepsy include: sleep paralysis and hypnagogic hallucinations. Narcolepsy results from the loss of hypocretin-1 and hypocretin-2, neurotransmitters produced by neurons located in the hypothalamus and brain stem.

Narcolepsy’s prevalence is approximately 25-50 per 100,000 people in the general population. Despite the multifactoral components present in narcolepsy, genetic factors play an integral role in disease manifestations, with the DQB1*0602 haplotype present in 95% of narcolepsy patients presenting with cataplexy. Genomic studies have also demonstrated a strong association of polymorphisms in the TCRα and TNFSF4 loci and narcolepsy, suggesting an autoimmune connection. Secondary narcolepsy is often associated with tumors, strokes, and vascular malformations in areas of the posterior hypothalamus or midbrain. Secondary narcolepsy is thought to be a result of direct brain injury, not the DQB1*0602 haplotype.

  • Confirmative testing for patients with a clinical diagnosis of narcolepsy
  • Supportive testing of patients presenting with an uncharacterized sleep disorder
  • Supportive testing of individuals with inconclusive clinical histories and sleep studies

Positive for Narcolepsy: HLA-DQB1\*06:02 allele detected. Positive results does not establish a diagnosis of narcolepsy in the absence of other clinical support.

Negative for Narcolepsy: HLA-DQB1\*06:02 allele not detected. Negative results will decrease, but not eliminated diagnosis of narcolepsy. HLA-DQB1\*06:02 genotyping does not evaluate other genetic and non-genetic factors contributing to a narcolepsy diagnosis.

Negative for mutations analyzed (No mutation detected)

Polymerase Chain reaction (PCR) with amplification refractory mutations systems (ARMS) or allele specific primer extension (ASPE) PCR with melt curve analysis, PCR with fluorescence monitoring, PCR with sequence specific oligonucleotide probes (SSO), and /sequence based typing (SBT), Sequencing.

Whole blood EDTA, or ACD. 

Samples stable at room temp or may be refrigerated. Frozen samples are unacceptable.

Stability

  • Ambient: 5-7 days
  • Refrigeration: 7-14 days
Multiple sleep latency test (MSLT), nocturnal polysomnography (NPSG), hypocretin – 1 level, melatonin level, complete blood count (CBC), platelet count, glucose level, drug screening panel (when appropriate).
3-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login